Evaluation of Anti-cancer Potential of Epigallocatechin and Berberine Loaded Chitosan Nanoparticle in Ehrlich Ascites Carcinoma Bearing Mice

The goal of this study was to determine how the chitosan nanoparticle (EBNP) loaded with berberine and epigallocatechin gallate (ECGC) affected the Ehrlich Ascites Carcinoma (EAC) tumour cell line and its anti- cancer effects. The EAC cells were used to studythe serum biochemical measures, endogenous antioxidants, lipid peroxidation biomarkers (MDA), histopathological, and haematological parameters. The in vitro cytotoxicity test revealed that EBNP’s IC50 value was 48.55 μgm. In EAC-bearing mice, biochemical measureslike total protein, creatinine, bilirubin, SGPT, SGOT, and ALP levels increased. Administering EBNP at high and low doses reduced the raised level to the point closest to normal. The haematological parameters like WBC, ESR, and CRP level increased in EAC bearing mice and the administered nanoformulation reduced the level significantly. The liver homogenatein EAC bearing mice showed that anti-oxidant enzymes such as SOD, catalase, GSH, GPXand GST level drastically declined. The EBNP nanoformulation elevated this level significantlyin a dose dependent manner. In mice with tumours, the level of the lipid peroxidation marker MDA increased. The discovery that MDA level decreased in comparison to control demonstrated the effectiveness of the nanoformulation in preventing lipid oxidativedegradation. The 5-Flouro uracil was usedas std for comparison and all the results arestatistically treated to verify its significance at P<0.05 level. Based on the histological studieson kidney and liver, EBNP nanoformulation hadreversed the kidney and liver damage. The findings showed that thetumour can be targeted by encapsulating epigallocatechin gallate (ECGC) + berberinein chitosan. Hence the EBNP nanoformulationcan be used in cancer therapy as possible potential drug candidates.